NCT07075939 Centralization and Oncologic Outcomes in Ovarian Cancer
| NCT ID | NCT07075939 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Condition | Epithelial Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-27 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-06-27 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia. The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithelial ovarian cancer (EOC) from 2018 to 2023. The retrospective component includes patients treated between 2018 and 2023, while the prospective component consists of clinical follow-up of those patients over the next five years.
Eligibility Criteria
Inclusion Criteria: * Female patients aged between 18 and 99 years * Histological and/or cytological diagnosis of epithelial ovarian cancer * Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia * Patients treated between January 1, 2018, and December 31, 2023 * Availability of clinical records and outcome data * Signed informed consent where possible, in accordance with GDPR and Italian regulations Exclusion Criteria: * Patients without histological or cytological confirmation of epithelial ovarian cancer * Incomplete or missing data for key clinical indicators * Patients unable to provide informed consent and for whom recontact is not possible * Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)
Contact & Investigator
Vincenzo Dario Mandato, MD - Principal Investigator
✉ vincenzodario.mandato@ausl.re.it📞 +39 0522 295467
Vincenzo Dario Mandato, MD
PRINCIPAL INVESTIGATOR
Azienda USL - IRCCS di Reggio Emilia
Frequently Asked Questions
Who can join the NCT07075939 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 99 Years, studying Epithelial Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07075939 currently recruiting?
Yes, NCT07075939 is actively recruiting participants. Contact the research team at vincenzodario.mandato@ausl.re.it for enrollment information.
Where is the NCT07075939 trial being conducted?
This trial is being conducted at Carpi, Italy, Mirandola, Italy, Pavullo nel Frignano, Italy, Sassuolo, Italy and 3 additional locations.
Who is sponsoring the NCT07075939 clinical trial?
NCT07075939 is sponsored by Azienda USL Reggio Emilia - IRCCS. The principal investigator is Vincenzo Dario Mandato, MD at Azienda USL - IRCCS di Reggio Emilia. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.